News

Sir Nigel Shadbolt joins BenevolentAI as a non-executive director

We are thrilled to announce Sir Nigel Shadbolt has joined our Board of Directors as a non-executive.

 At BenevolentAI, we build technology to advance scientific discovery and ultimately to make a positive impact on patient outcomes. We recognise that delivering on our mission demands collaboration with world-leading experts and we could not wish for more wisdom, knowledge and expertise than that of Sir Nigel Shadbolt. 

Sir Nigel is a visionary and pioneer in AI and computer science with an academic career reaching back to 1978, when he began a PhD at Edinburgh University’s Department of AI. During his academic career he established internationally recognised research groups at the Universities of Nottingham, Southampton and Oxford. Sir Nigel is now Principal of Jesus College, Oxford and a Professor in the Department of Computer Science at the University of Oxford where he researches and leads a group on human-centred computing and AI. In 2009, he was appointed as Information Advisor to the UK government and helped establish the UK as a leading force in the publication and use of open data. He is Chairman of the Open Data Institute, which he founded in 2012 with Sir Tim Berners Lee with the purpose of building an open, trustworthy data ecosystem. He was one of the originators of the interdisciplinary field of Web Science, the study of the large-scale socio-technical system that is the World Wide Web. He is a Director and Trustee of the Web Science Trust, which promotes policy, research and teaching in this emerging area.  

Sir Nigel’s research into the Semantic Web forged the way for new companies, such as Garlik, acquired by Experian in 2011. He continues to research and advocates for open data – identifying where it can be used to promote economic and social value. Recent work on the theory and practice of ‘social machines’ is leading the way in integrating humans and computers in novel and unanticipated ways so as to augment our problem solving capabilities. As an interdisciplinary researcher, policy expert and scientific commentator, Sir Nigel brings with him an unrivalled depth of experience and technical background in tech, AI and data.

Our core purpose at Benevolent is summarised by our mantra, ‘because it matters’. Behind this, sits a team of passionate and dedicated people whose curiosity, humility and openness to learning are what will allow us to progress on the complex problems we are tackling, and ultimately, will be what leads us to discover new vital treatments for patients. We are excited to integrate Sir Nigel’s expertise and knowledge into our board and to count him as part of this team and mission.


Sir Nigel Shadbolt commented:

“At its best AI augments human ingenuity and creativity. BenevolentAI combines human expertise with the latest AI and machine learning methods to provide extraordinary potential for drug design and discovery. I am delighted to be a part of their journey.”

Joanna Shields, CEO
More Posts

You Might Also Like

News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021